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Summary 
Bcl-2 belongs to a family ofapoptosis-regulatory proteins which incorporate into the outer mi- 
tochondrial  as  well  as  nuclear  membranes.  The  mechanism by which  the  proto-oncogene 
product Bcl-2 inhibits apoptosis is thus far elusive. We and others have shown previously that 
the  first biochemical alteration  detectable in  cells  undergoing  apoptosis,  well before nuclear 
changes become manifest, is a collapse of the mitochondrial inner membrane potential (AXltm), 
suggesting the involvement ofmitochondrial products in the apoptotic cascade. Here we show 
that mitochondria contain a pre-formed ~50-kD protein which is released upon A~  m disrup- 
tion  and  which,  in  a  cell-free  in  vitro  system,  causes  isolated  nuclei  to  undergo  apoptotic 
changes such as chromatin condensation and intemucleosomal DNA fragmentation. This apop- 
tosis-inducing factor (AIF) is blocked by N-benzyloxycarbonyl-Val-Ala-Asp.fluoromethylke- 
tone  (Z-VAD.fmk), an antagonist  of interleukin-1]3-converting  enzyme (ICE)-like proteases 
that is also an efficient inhibitor of apoptosis in cells. We have tested the effect of Bcl-2 on the 
formation, release, and action of AIF. When preventing mitochondrial permeability transition 
(which accounts for the pre-apoptotic A~  m disruption in  cells),  Bcl-2 hyperexpressed in the 
outer mitochondrial membrane also impedes the release of AIF from isolated mitochondria in 
vitro. In contrast, Bcl-2 does not affect the formation of AIF, which is contained in comparable 
quantities in control mitochondria and in mitochondria from Bcl-2-hyperexpressing cells. Fur- 
thermore, the presence of Bcl-2 in the nuclear membrane does not interfere with the action of 
AIF on the nucleus,  nor does Bcl-2 hyperexpression protect cells against AIF. It thus  appears 
that Bcl-2 prevents apoptosis by favoring the  retention  of an apoptogenic protease in  mito- 
chondria. 
B 
efore cells manifest nuclear signs ofapoptosis, they dis- 
rupt  the  mitochondrial  transmembrane  potential 
(ARtm) 1.  This  pre-apoptotic  AXI*,,~ collapse  occurs  in  nu- 
~Abbreviations used in  this paper: Ac-DEVD.CHO, acetyl-Asp-Glu-Val- 
Asp-aldehyde; Ac-YVAD.CHO; acetyl-Tyr-Val-Ala-Asp-aldehyde;  Ac- 
YVAD.cmk, aceyl-Tyr-Val-Ala-Asp-chloromethylketone;  AIF, apoptosis- 
inducing factor; Atr, atractyloside; CMXP,.os, chloromethyl-X-rosamine; 
Axlt,,,, mitochondrial transmembrane potential; mC1CCP, carbonylcya- 
nide m-chlorophenylhydrazone;  Neo, neomycin resistance gene; MDH, 
malate dehydrogenase; MAO, monoamine  oxidase; PI, propidium iodine; 
PT, pemleability  transition; P,  OS, reactive oxygen species; SDH, succi- 
hate dehydrogenase; t-BHP, ter-butylhydroperoxide; TLCK, N-tosyl- 
t-lysyl chloromethylketone; TPCK, N-tosyl-l-Phe-chloromethylketone; 
PARP, poly (ADP-ribose) polymerase;  Z-D.CH2-dcb, N-benzyloxycar- 
bonyl-Asp-CH20C(O)-2-6,-dichlorobenzene;  Z-FA.fmk,  N-benzyloxy- 
carbonyl-Phe-Ala-fluoromethylketone;  Z-VAD.fmk,  N-benzyloxycarbo- 
nyl-Val-Ala-Asp-fluoromethylketone. 
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merous  cell  types  (neurons,  fibroblasts,  myelomonocytic 
cells,  lymphocytes, hepatocytes),  irrespective of the  apop- 
tosis inducer or the presence of mitochondrial DNA  (1-5 
and references cited therein).  As to the mechanism of the 
pre-apoptotic A~  m disruption, it appears that it is mediated 
by so-called "permeability transition (PT) pores", i.e., reg- 
ulated megachannels that allow for the dissipation of inner 
transmembrane  ion  gradients.  Thus,  a  series  of  drugs 
known for their PT-inhibitory potential (6,  7)  such as cy- 
closporin A  (which  acts as a transient inhibitor of PT, via 
mitochondrial cyclophilin) or bongkrekic acid  (which acts 
as a stable inhibitor of PT, via specific binding to the inner 
membrane adenine nucleotide translocator) inhibit the pre- 
apoptotic A~  m collapse (2, 4). Bonkrekic acid is also an ef- 
ficient inhibitor of other manifestations of apoptosis at the 
levels  of the  nucleus  (chromatin  condensation  and  DNA 
fragmentation),  of the  cytoplasma (depletion  of non-oxi- 
dized glutathione and hyperproduction of reactive oxygen 
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phatidylserine residues  in  the  outer  membrane  leaflet,  in- 
crease in permeability) (4, 8). Altogether these findings sug- 
gest that mitochondrial PT may be an important common 
event  of the  effector phase  of the  apoptotic process.  This 
idea  is  underlined  by  the  observation  that  mitochondria 
undergoing PT acquire the capacity to induce nuclear apop- 
tosis in an in vitro system (4).  A  further argument in favor 
of the implication of PT in apoptosis regulation is the find- 
ing that  the  apoptosis-inhibitory proto-oncogene  product 
Bcl-2  functions  as an  endogenous  PT  inhibitor. This  PT- 
protective  Bcl-2  effect  has  been  observed  in  the  overall 
context  of the  intact  cell  (2),  as well  as  in  isolated mito- 
chondria (4), suggesting that PT may indeed constitute the 
(or one of the)  Bcl-2-regulated checkpoint(s)  of the apop- 
totic  cascade.  It has  remained obscure,  however,  how  the 
putative Bcl-2/PT  checkpoint could be related to  another 
apoptosis checkpoint  controlled by a  cascade  of proteases 
belonging to the expanding ICE/CPP32/Ced-3  family (9- 
11),  especially in  view  of the  fact  that  Bcl-2  can  regulate 
the activation of at least some of these proteases (12). 
Based on the findings of other investigators (13-17), we 
have recently developed a cell-free system ofapoptosis. Us- 
ing such a  system, we observed that isolated mitochondria 
induced to undergo PT in vitro release a  heat-labile >10- 
kD  factor  capable  of inducing  isolated  nuclei  to  rapidly 
(~<15  rain)  manifest  apoptotic  changes  such  as  chromatin 
condensation  and  oligonucleosomal  DNA  fragmentation 
(4). This finding suggested a direct molecular link between 
pre-apoptotic Axlt,, disruption and nuclear apoptosis. In the 
present paper,  we  report  the  biochemical characterization 
of the  apoptogenic  factor  released  by  mitochondria.  In- 
triguingly, this factor possesses a  protease activity which is 
neutralized by a degenerate tripeptide inhibitor of ICE-like 
proteases, suggesting a  direct relationship between PT  and 
protease  activation during  the  effector phase  of apoptosis. 
In  addition,  we  characterized  the  effect  of Bcl-2  on  the 
production, release, and action of this mitochondrial apop- 
tosis-inducing  factor  (Alia).  Our  data  indicate  that  Bcl-2 
solely interferes with the PT-dependent release of AIF, yet 
does not neutralize its lethal action. These data may provide 
major clues for the understanding of apoptosis regulation. 
Materials  and Methods 
Orga~lsand  Cell Lim's.  Livers  were  obtained  from  female 
Balb/c mice (6-8 wk of age) subjected to perfusion of the portal 
vein  with  isotonic  PBS  (pH  7.2;  5  ml  at  room  temperature). 
2B4.11  T  cell  hybridoma  cell  lines  stably transfected with  an 
SFFV.neo vector containing the human  bcl-2 gene or the neo- 
mycin  (Neo)  resistance  gene  only  were  kindly  provided  by 
Jonathan Ashwell (National Institutes of Health, Bethesda, MD). 
In this cell line, Bcl-2 overexpression confers resistance to  most 
but  not  all  apoptosis-inducing stimuli  (18).  These  cell lines,  as 
well  hun:an  fibroblast-like  HeLa  cells,  were  cultured  in 
R.PMI1640 medium supplemented with 1-glutamine, antibiotics, 
and 10% decomplemented FCS. 
hductiol~ of Apoptosis  in Cells.  T  cell hybridoma cells were cul- 
tured during 8 h in the presence of the indicated concentration of 
ter-butylhydroperoxide  (t-BHP),  carbonylcyanide m-chlorophe- 
nylhydrazone  (mCICCP),  C2-ceramide  (Sigma,  Chem  Co.,  St. 
Louis, MO), N-benzyloxycarbonyl-Val-Ala-Asp.fluoromethylke- 
tone  (Z-VAD.fmk; Enzyme  Systems, Dublin,  CA),  and/or the 
membrane-permeant  specific  inhibitor  of  interleukin-1]3-con- 
verting enzyme (ICE) Ac-YVAD.cmk (Bachem, Basel,  Switzer- 
land). The frequency of subdiploid cells was determined by pro- 
pidium iodine staining of ethanol-fixed cells. In some experiments, 
Bcl-2-or vector-transfected cells  (I  ￿  10") were  permeabilized 
with saponin  (5 mg/ml)  in the presence of CFS buffer (see be- 
low) or purified AIF (1  ~g/300 ILl), then washed twice (l,()00,4, 
10  rain),  and  cultured for 60  xnin  in  CFS buffer,  Then,  1)NA 
fragmentation was assessed using terminal desoxyribonucleotidyl- 
transferase  to  incorporate Fluorescein-12-dUTP into  permeabi- 
lized cells, following the manufacturer's protocol (TUNEL method; 
Boehringer Mannheim, Mannbeim, Germany). 
Pmjfication  of Orcanelles.  Mitochondria  were  purified  on  a 
Percoll  |  (Pharmacia,  Uppsala,  Sweden)  gradient  (19)  and  were 
stored on ice in B buffer (400 mM mannitol; 10 mM KH2PO4, 5 
mg/ml BSA, 50  mM TRIS-HC1,  pH 7,2)  for up to 4 h.  Mito- 
chondria were washed and resuspended in cell-free system (CFS) 
buffer (220 mM mannitol; 68 mM sucrose, 2 mM NaC1, 2.5 mM 
PO4H2K,  0.5  mM  EGTA,  2  mM  MgCI>  5  mM  pyruvate, 0.1 
mM phenylmethyl sulfonylfluoride [PMSF],  1 mM  dithiotreitol, 
10 mM Hepes-NaOH, pH 7.4)  before manipulation (4). Submi- 
tochondrial fractions were  obtained as described (20).  Osmotic 
shock of mitochondria leading to the disruption of the outer but 
not of the inner membrane or digitonin lysis (1.2%) of the outer 
mitochondrial  membrane  for  the  obtention  of intermembrane 
proteins was performed according to standard methods (20). The 
four mitochondrial compartments (inner +  outer membrane, in- 
termembrane, matrix) were identified by the specific activities of 
the  marker enzymes monoamine  oxidase  (MAO)  for the  outer 
membrane,  succinate dehydrogenase (SDH)  for the inner me:n- 
brahe, and malate dehydrogenase (MDH) for the matrix (21). En- 
zyme activities were determined as described (21)  and expressed 
as specific activities (nmol of transformed substrate ￿  n:g-I total 
protein  X  rain-I).  Freeze-thawing of intact  mitochondria  was 
performed in two cycles (liquid nitrogen followed by 37~  dur- 
ing 5 min). Ultrasonication was carried out using a Branson soni- 
cator (model 130;  Danbury, CT;  20 kHz, 400  W, 5 n:in, 4~ 
In one  experiment, the AIF-containing intermembrane fraction 
was  treated by proteinase  K  digestion  (100  ixg/lnl,  10  min  at 
37~  Boehringer Mannheim,  Mannheim,  Germany),  followed 
by proteinase K  inactivation by addition of /mM  PMSF  (22). 
Nuclei from  the  indicated cell type were  purified on  a  sucrose 
gradient and conserved in 50% glycerol (Sign:a)  in HNB buffer, 
at 20~  for a maxinmm of 15  d, as described (13,  23).  The ex- 
pression of Bcl-2 on the surface  of isolated nutochondria or nu- 
clei was determined using an FITC-labeled hBcl-2-specific anti- 
body  (1  Ixg/ml, 30  rain  at  4~  clone  124;  1)AKO,  Glostrud. 
Denmark). 
Determination  ~f Apwtogenic Effects on Isolated Nuclei.  For  the 
standard assessment ofchromatin condensation, nuclei from HeLa 
cells  were  purified on  a  sucrose  gradient as above,  washed  2￿ 
(1,000  ,G  10  rain, 4~  and resuspended m  CFS buffer.  In stan- 
dard conditions, nuclei (103 nuclei/bLl  ) were cultured in the pres- 
ence of mitochondrial preparations for 90  rain at 37~  Nuclei 
were  stained with  4'-6-diamidino-2-phenylindole dihydrochlo- 
ride (DAPI; 10 txM; Molecular Probes, Leiden, The Netherlands) 
and examined by fluorescence  microscopy (13,  14). A minimun: of 
200 events were scored and nuclei presenting chromatin conden- 
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tic  (4). Alternatively,  nuclei were stained  with propidium iodide 
(PI;  10 Izg/ml; Sigma  and the lipophilic  dye 5-methyl-bodipy- 
3-dodecanoic  acid  (100  riM;  Molecular  Probes),  followed  by 
cytofluorometric analysis in a EPICS Profile II Analyzer  (Coulter, 
Hialeh,  FL). Only  membrane-surrounded  (5-methyl-bodipy- 
3-dodecanoic acid-labeled)  particles  were gated on. A good cor- 
relation  between  the  frequency of nuclei  exhibiting  chromatin 
condensation with DAPI and hypoploidy with PI was  obtained 
(S.A. Susin and G.  Kroemer, manuscript in preparation).  In one 
series  of experiments,  nuclei  from  Neo-  or  Bcl-2-transfected 
T cell  hybridoma  cells were  subjected  to  transmission  electron 
microscopy, as  described  (8). Furthermore,  in  one  experiment, 
nuclei were pretreated with Z-VAD.fmk (1  mM, 60 min, 37~ 
in CFS buffer),  washed 3￿  (1000 g; 10 rain),  and exposed to mi- 
tochondrial factors. 
Purification q[ the  Mitochondrial Apoptosis-inducing Factor (AIF). 
Purified hepatocyte mitochondria were treated  with atractyloside 
(5 mM; Atr; Sigma) to induce PT and liberation of AIF (4). Su- 
pernatants  (150,000  g;  1 h; 4~  from these  mitochondria were 
concentrated  on  Centricon 10  membranes  (i>10  kD;  Amicon 
Inc., Beverly,  MA), which retains the entire AIF activity  (4), and 
then subjected to a Pharmacia MonoQ (HR5/5)  FLPC column 
pre-equilibrated  with protein-free  CFS buffer.  Elution was per- 
formed on a linear gradient from 0 to 250 mM NaC1 at 0.5 ml/ 
min over 30 rain,  followed by elution at 1 M from min 33. After 
dialysis (10 kD membrane) in CFS buffer,  all fractions  were sub- 
jected to the assessment ofpro-apoptotic activity.  The active frac- 
tion (eluting at  110 mM NaC1) was dialyzed  against protein-free 
CFS  buffer  (4~  4  h,  5,000￿  excess  of CFS  buffer)  and  sub- 
jected to re-injection into the Phamlacia MonoQ FLPC column 
(5  Ltg; elution as described  above).or a reverse  phase  C-18 col- 
umn coupled to a Hewlett Packard 1090 HPLC apparatus  (eluted 
on a linear gradient from 0.1% trifluoracetic  acid.in water to 0.1% 
trifluoracetic  acid.in acetronitrile  at  I  ml/min over 30 min).  The 
SDS-PAGE  (12%; performed  in  reducing  conditions:  1  mM 
dithiotreitol)  of AIF purified by anion exchange chromatography 
(concentrated on a Centricon 10 membrane; 2 >g) was subjected 
to  Silver  staining  (BioRad,  Hercules,  CA).  Alternatively,  AIF- 
containing supernatants  or AIF purified on the MonoQ column 
were  fractionated  on  a  Pharmacia  Superdex75  column  equili- 
brated with CFS buffer.  All fractionation steps had to be carried 
out at 4~  to avoid loss of biological AIF activity.  To determine 
the inhibitory profile of  AIF, different protease inhibitors were added 
to  purified  AIF  or  AIF-containing preparations:  Z-VAD.fmk; 
N-benzyloxycarbonyl-Phe-Ala-fluoromethylketone  (Z-FA.fink; 
Enzyme  Systems),  N-tosyl-t-Lys-chloromethylketone  (TLCK; 
SiNna), N-tosyl-r-Phe-chloromethylketone (TPCK), E64, leupep- 
tin,  p-chloromercuryphenylsulfonic  acid,  N-phenylmaleimide 
(Sigma), calpain  inhibitors I and II (Boehringer),  or modified tet- 
rapeptides and N-benzyloxycarbonyl-Asp-CH2OC(O)-2-6,-dichlo- 
robenzene (Z-D.CH2-dcb; Bachem). 
Quantitation of Mitodlondrial Permeability Transition (PT).  For  the 
induction of PT, mitochondria from different  cell lines were in- 
cubated with the indicated doses of Atr,  t-BHP or mC1CCP (4). 
The A~n, was  measured using the A~ncsensitive cationic lipo- 
philic  dye chloromethyl-X-rosamine (CMXRos; 10 nM; 15 min 
at 37~  Molecular Probes)  (5), after having added the indicated 
PT inducer  (15 rain,  37~  Mitochondria were analyzed  in an 
Elite  cytofluorometer  (Coulter).  All  A~,~ determinations  were 
performed at least three times in each experiment. 
Determinations of Protease and DNAse Aaivity.  AIF-mediated cleav- 
age of nuclear substrates is indicated  by the comparative analysis of 
Coomassie-stained SDS-PAGE of HeLa nuclei  (5 ￿  106/lane)  cul- 
tured in the presence or absence of 100 ng/ml purified AIF (90 min, 
37~  The degree ofpoly(ADP-ribose) polymerase (PAl<P) and 
lamin  cleavage was determined  by immunoblots,  using the mono- 
clonal antibodies  C2-10 (purchased  from Guy Poirier,  Montreal 
University,  Canada)  and E6  (kind  gift  from Dr.  E.  Nigg,  Lau- 
sanne  University,  Lausanne,  Switzerland),  respectively  (14,  24, 
25).  Positive  controls were human T lymphoma cells exposed to 
anti-Fas  antibody  (500  ng/ml;  4  h;  Immunotech,  Marseille, 
France).  Endonuclease  activity  was  determined  on  supercoiled 
pUC DNA (500 ng in CFS buffer;  120 min; 37~  followed by 
ethidium bromide agarose gel (1%) electrophoresis. 
Results 
Localization and Purification of AIF.  Supernatants  from  mi- 
tochondria  that  have  undergone  PT  but  not  those  from 
control mitochondria induce signs of apoptosis such as nu- 
clear  chromatin  condensation  in  a  cell  free  system  (4). 
Thus, mitochondria treated with the PT inducers atractyloside 
(Atr,  a  specific ligand  of the adenine  nucleotide  transloca- 
tot),  mCICCP  (a  protonophore)  and  t-BHP  (a  pro- 
oxidant)  release  an  apoptogenic  activity into  the  superna- 
tant  that  we  have  baptized  "apoptosis-inducing  factor" 
(AIF)(Fig.  1).  In addition to these PT-inducing treatments, 
destruction ofmitochondrial membranes via sonication, os- 
motic  shock,  or  digitonin  treatment  (which  specifically 
lyses the  outer but  not the  inner  membrane,  yielding the 
intermembrane  fraction of proteins)  (20)  also releases AIF, 
indicating that AIF is pre-fomled. Whereas,  the fraction of 
soluble intermembrane  products does contain AIF activity, 
neither purified  mitochondrial  membranes  nor the soluble 
products of the mitochondrial matrix are apoptogenic (Fig.  1, 
Table  1). Thus, AIF is not found in submitochondrial frac- 
tions that contain high specific activities of marker enzymes 
for the outer membrane  (MAO),  inner membrane  (SDH), 
and matrix (MDH)  (Table  1). Proteinase K treatment ofin- 
termembrane proteins destroys AIF activity, indicating that 
AIF  is  a  protein  (Fig.  1).  Ion  exchange  chromatography 
yields only one AIF activity which elutes at 110 mM NaC1 
(Fig. 2 A). The AIF-containing fraction purified on an an- 
ion  exchange  column  contains  only one  major protein  as 
determined by four different methods: reinjection into the 
same anion exchange FPLC column (Fig. 2  B), analysis on 
a  reverse  phase  HPLC  column  (which  separates  proteins 
based  on  their  hydrophobicity;  Fig.  2  C),  separation  in  a 
molecular sieve  FPLC column  (Fig.  2  D)  and SDS-PAGE 
revealed by the sensitive silver staining technique  (Fig.  2  E). 
Thus, anion exchange chromatography (Fig. 2 A), molecu- 
lar sieve chromatography (Fig. 2  D),  and SDS-PAGE (Fig. 
2  E)  identify  hepatocyte AIF as  a  single  ~50-kD  protein 
with  an estimated  isoelectric point of 5.5.  AIF purified on 
an anion exchange column (Fig. 2 A) is homogenous with 
regard to charge (Fig. 2  B), hydrophobicity (Fig. 2  C), and 
apparent  molecular  weight  in  both  denaturing  and  non- 
denaturing conditions  (Fig. 2, D  and E).  AIF is low-abun- 
dant  (<0.1%  of mitocbondrial  proteins)  and  labile  at  room 
temperature,  requiring  purification  at  4~  AIF activity is 
1333  Susin  et al. Figure  1.  Submitochondrial localization  of mitochondrial apoptosis- 
inducing factor (AIF). Isolated HeLa nuclei were cultured in the presence 
of various  preparations of mouse hepatocyte mitochondria: ultracentri- 
fuged supematants of mitochondria (10 mg protein/ml) treated with Atr (5 
raM), mC1CCP (100 p.M), t-BHP (50 IxM), osmotic shock,  or ukrasoni- 
cation; soluble products (200 p.g protein/roll of the mitochondrial matrix, 
purified inner and outer mitochondrial membranes, or soluble  factors of 
the intem~embrane space. After 90 rain of culture at 37~  the frequency 
of nuclei exhibiting chromatin condensation was assessed by labeling with 
DAPI. Proteinase  K digestion ofintennembrane proteins was followed by 
addition of 1 mM PMSF for its inactivation, as described in Materials and 
Methods. P,  epresentative  DAPl-stained HeLa nuclei (>70 % of the phe- 
notype) cultured in the presence of untreated or proteinase K-inactivated 
intermembrane preparation are shown. 
detected  in  mitochondria  from  several  cell  types  (liver, 
heart,  brain,  myelomonocytic  cells,  lymphoid  cells)  and 
species  (mouse,  human),  suggesting that it is an ubiquitous 
protein.  Moreover,  the  physicochemical  characteristics  of" 
this protein appear  approximately  the  same  for hepatocyte 
and lymphocyte  AIF  (not shown).  Purified AIF  suffices to 
induce the whole pattern ofapoptotic  nuclear alterations in 
vitro:  eccentric  DNA  condensation  resembling  that  ob- 
served in apoptotic  cells, oligonucleosomal  DNA  fragmen- 
tation, and hypoploidy  (Figs.  3  and 6  C; see below). 
In synthesis, it appears that AIF is one pre-fom~ed,  solu- 
ble mitochondrial intermembrane  protein. 
AIF  Possesses  a  Proteolytic  Activity  That  Is  Inhibited  by 
Z-VAD:fmk.  To  gain information on the mode  of action 
of AIF,  we determined  the inhibitory profile of this Factor. 
The  chromatin condensation-inducing activity of AIF is in- 
hibited  by  the  thiol  reagents  p-chloromercuryphenyl- 
sulfonic  acid  (IDs,  :'-250  IxM)  and  N-phenylmaleimide 
(IDs0 :"50  ~M)  but not by specific  inhibitors of different 
calcium,  serine,  or  cysteine  proteases  including specific  in- 
hibitors of ICE  (Ac-YVAD.cmk,  Ac-YVAD.CHO:  no in- 
hibiton at  doses  as high as  1  raM)  and  CPP32/Yama  (Ac- 
DEVD.CHO)  (reference 4  and Fig.  3  A).  The only selective 
protease inhibitor which blocks AIF activity is Z-VAD.fmk 
(Fig.  3  A;  ID>  :"30  ~M),  an inhibitor of ICE-like proteases 
Figure 2.  Biochenfical  charac- 
terization  of  AIF.  (A)  Anion 
exchange  purification  of  AIF. 
Concentrated supernatants  from 
Atr-treated  hepatocyte  mitochon- 
dria were subjected to a MonoQ 
FLPC  column  pre-equilibrated 
with  CFS  buffer.  Elution  was 
performed  on  a  linear  gradient 
from 0 to 250 mM NaC1 at (}.5 
ml/nfin over 30 rain while mon- 
itoring the OD280 ~dl li,e). Af- 
ter dialysis (10 kl) membrane) in 
an excess of CFS buffer,  all frac- 
tions were  subjected  to  the  as- 
sessment  of pro-apoptotic activ- 
ity  (circles). Only  one  fraction 
eluting at 110 mM NaCI was bi- 
olo~cally active.  (/3) Reinjcction 
of  the  A1F-containing  fi'action 
eluting at 110 mM into an amon 
exchange  colunm.  AIF  (5  p.g 
protein) purified as in A and dia- 
lyzed  in  excess  CFS  buffer  was 
illjected  into a  MonoQ  colunm 
in the same conditions of elution 
as  in  A,  and  the  O1)280  was 
monitored.  The  background 
OD280 obtained with CFS buffer only was subtracted.  (C) Analysis of AIF  (5 Ixg, purified on an anion exchange column as in A) iu a reverse  phase 
HPLC colunm, followed by monitoring of the OD280 (background values subtracted).  (/3) Molecular sieve FPLC purification ofAIF. A[F-contaiuing 
supernatants  (OD280: full line) were fractionated on a Superdex75  column equilibrated with CFS buffer, followed by the biological  assay (circh's). Pro- 
teins with a known molecular weight were employed to calibrate the FPLC column (arrows). Equivalence calculations indicate that/>80% ofAIF activ- 
i  W arc recovered from the columns. In addition, AIF (5 I.Lg) purified on the anion exchange colunm as in A was analyzed on the Superdex  75 colunm 
while monitoring the OD280 (dotted line). (El SI)S-PAGE of AIF (2 btg; purified as in A) in reducing conditions. Proteins were detected using a com- 
mercial Silver staining kit, as described in Materials and Methods. 
1334  Mechanism of Bcl-2-mediated Apoptosis Inhibition Table  1.  Distribution of AIF in Mitochondrial Compartments 
Marker enzymes 
MAO  SDH  MDH  AIF Activity 
mmol/mg /min ++- SD  % apoptosis 
Mitochondria (freeze-thawed)  52  4-  9  517  +  149  2812  -+  265  67  +-  12 
Outer membrane  503  +  46  555  _+  186  1028  +  364  14  +_  6 
Intermembrane space  2  +  1  10  4-  6  831  -+  220  85  +  7 
Inner membrane  2  +  2  2411  +  268  1416  +  184  <5 
Matrix  1  +  1  <5  4054  --- 880  8  +  3 
Submitochondrial fractions were purified as described in Materials and Methods. Marker enzymes were measured using colorimetric approaches on 
synthetic substrates. AIF activity was determined for each fraction (200  Ixg protein/ml) as in Fig. 1. Results are mean values +- SD of four indepen- 
dent experiments. 
(26-28).  By virtue  of its tripeptidic  structure,  Z-VAD.fmk 
is thought  to be a  less specific protease  inhibitor  than  con- 
ventional  tetrapeptidic  inhibitors  of ICE  or  CPP32/Yama 
(26-28).  Z-VAD.fmk  does not  neutralize  AIF by virtue  of 
its  N-benzoylcarbonyl  (Z)  or  fluoromethylketone  (fmk) 
groups,  because  the  control  molecule  Z-FA.fmk  (which 
only  differs from  Z-VAD.fmk  in  its  amino  acid  sequence: 
FA  instead of VAD)  does  not  inhibit AIF  activity  at  doses 
as high as  1  mM  (Fig.  3  A  and data not shown).  Altogether 
these  data  suggest  that  AIF  possesses a  cysteine-dependent 
Figure  3.  Inhibitory profile  of AIF.  (A) 
Screening of  various protease inhibitors. Pu- 
rified AIF (50 ng/ml) was tested for apopto- 
sis-inducing activity  on  HeLa  nuclei  as  in 
Fig.  1,  in the presence of a number of dif- 
ferent protease inhibitors. The range of  neg- 
ative data are shown for different inhibitors 
used  at  concentrations  of  either  50  txM 
(TLCK, TPCK, E64,  calpain inhibitors I and 
II, leupeptin) or 250  I.tM  (Ac-YVAD.cmk, 
Ac-YVAD.CHO,  Ac-DEVD.CHO,  Z-D. 
CH2-dcb, Z-FA.fmk). (B) Inhibition of the 
AIF activity contained in supernatants from 
Atr-treated  mitochondria.  Nuclei  were 
treated at the same time with such superna- 
tants and/or 100 txM Z-VAD.fmk. Alterna- 
tively, the supernatant was pretreated with 
Z-VAD.fmk  (100  ￿  ~M;  30  rain,  37~ 
followed  by  dialysis  (4~  4  h,  5,000￿ 
excess  of  CFS  buffer)  for  removal-of 
Z-VAD.fmk and testing for apoptotic activ- 
ity  on  isolated  HeLa  nuclei.  Furthermore, 
nuclei were pretreated with Z-VAD.fmk (1 
raM, 60 min, 37~  in CFS buffer), washed 
3￿  and exposed to the untreated AIF-con- 
taining supernatant, (C)  Z-VAD.fmk-medi- 
ated  inhibition  of AIF-induced  chromati- 
nolysis.  Nuclei  were  treated  with  CFS 
buffer only (control), purified AIF (100  ng/ 
nil),  or  AIF  pretreated  with  Z-VAD.fmk 
and dialysis.  Alternatively, nuclei were first 
treated with Z-VAD.fmk, then washed and 
cultured with AIF. Nuclei were stained with PI, as detailed in Materials and Methods, followed by cytofluorometric analysis, Percentages refer to the 
subdiploid population.  (D)  Z-VAI).fmk-mediated inhibition of AIF-induced DNA fragmentation. Isolated nuclei (1  ￿  10 ~') were cultured during 90 
min in the presence of purified AIF (100 ng/ml, lanes 3 and 4) and/or Z-VAD.fmk (100  btM, lanes 2 and 4) and analyzed by ethidium bromide agarose 
gel electrophoresis. (E) Effect of AIF on protease substrates and purified DNA. HeLa nuclei were exposed to CFS buffer only (1), the supernatant of dig- 
itonin-permeabilized mitochondria (2), or 100 ng/ml purified AIF (3). The degree of PARP and lamin cleavage was detemlined by immunoblots. Posi- 
tive controls (co)  are human lymphoma cells exposed to anti-Fas antibody. The same three preparations were tested for endonuclease activity on pUC 
DNA, followed by ethidium bromide agarose gel electrophoresis. 
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Figure  4.  Effect of  Z-VAD.fmk  and  transfection- 
enforced Bcl-2 hyperexpression on apoptosis induction in 
cells. T  cell hybridoma  cell lines stably transfected with 
vectors containing the human bob2  gene or the neomycin 
(Neo) resistance gene only were cultured during 8 h in the 
presence  of the indicated  apoptosis inducer and/or pro- 
tease inhibitor.  Apoptosis (subdiploidy) was quantified by 
propidium iodide staining of ethanol-fixed ceils. 
catalytic activity not identical with but related  to  ICE  and 
CPP32. 
Z-VAD.fmk  prevents  the  chromatin  condensation  in- 
duced  by  purified  AIF  as  well  as  by  supernatants  from 
Atr-treated mitochondria (Fig. 3,  B  and C), in accord with 
the  observation  that  AIF  seems  the  only  pro-apoptotic 
mitochondrial  factor  (Fig.  2,  A  and  C;  see  above). 
Z-VAD.fmk is an irreversible rather than competitive pro- 
tease  inhibitor  (26-28).  Accordingly,  pre-incubation  of 
AIF  with  Z-VAD.fmk  causes  a  durable  AIF  inactivation 
that persists after removal of Z-VAD.fmk (Fig. 3, B and C). 
In contrast, pre-incubation of nuclei with Z-VAD.fmk has 
no  significant protective  effect  against AIF  (Fig.  3,  B  and 
C),  thus  confirming that  Z-VAD.fmk  acts  on  AIF  rather 
than on the nuclear target(s)  of AIF. Z-VAD.fmk prevents 
all manifestations of apoptosis  induced by AIF:  chromatin 
condensation (Fig. 3, A  and B), DNA loss from nuclei (Fig. 
3  C) and oligonucleosomal DNA  fragmentation (Fig. 3  D). 
Mitochondria  contain  an  endonuclease  which  has  also 
been found in nuclei from thymocytes (29). Accordingly, a 
DNAse  activity is  found in  the  supernatant  of digitonin- 
treated mitochondria (Fig. 3  E). However, purified AIF has 
no  intrinsic DNAse  activity  (Fig.  3  E),  indicating that  it 
probably  induces  DNA  fragmentation  via  activating pre- 
existing nuclear DNAses.  Although  AIF  has  a  proteolytic 
activity on unidentified nuclear substrates of approximately 
28, 42, and 90 kD  (not shown), it fails to  cleave PARP  or 
lamin in isolated nuclei (Fig.  3  E).  Thus,  the nuclear sub- 
strate(s)  of AIF  must  be  different  from  those  cleaved  by 
prominent members of the ICE/CPP32  family ofproteases 
(11, 25, 30). 
If AIF was a  rate-limiting factor  of cell death,  its inhibi- 
tion should retard or inhibit nuclear apoptosis in cells. Ac- 
cording  to  the  literature,  the  AIF  inhibitor  Z-VAD.fmk 
prevents apoptosis  of mammalian and insect cells respond- 
ing to  a  variety of different lethal stimuli (26-28).  In addi- 
tion, as shown in Fig. 4, Z-VAD.fmk (but not its structural 
analogue Ac-YVAD.cmk,  a  specific  inhibitor of ICE)  in- 
hibits apoptosis induced by ceramide, the pro-oxidant t-BHP, 
or the protonophore  mC1CCP,  which acts  directly on the 
inner mitochondrial membrane  (Fig.  5).  This effect  is ob- 
tained at similar doses  as those  required to  inactivate puri- 
fied  AIF  ('--'60  I~M)  in  vitro  (Fig.  3  A),  underlining the 
probable role of AIF in apoptosis. 
In synthesis, it appears that mitochondria undergoing PT 
Figure  5.  Bcl-2-mediated  inhibition of mitochondrial  permeability 
transition (PT)-dependent  AIF release. (A) Effect of Bcl-2 on the A~,~ of 
isolated mitochondria  exposed to  different PT inducers m vitro,  Mito- 
chondria were purified from neo- or bcl-2-transfected cells, cultured dur- 
ing 15 rain in the presence of Atr (5 n~Vl), t-BHP (50 ~M), or mCICCP 
(10 IzM, continuous  line;  100 l.tM, dashed  line)  and then labeled with the 
A~,,,-sensitive dye CMXRos. Representative cytofluorometry profiles of 
2 ￿  104 mitochondria are shown. Note that low mCICCP concentrations 
reveal a  difference between mitochondfia  from  neo- and bcl-2-trans- 
fected cells but that this difference is overcome by a high mC1CCP dose. 
Similar results were obtained when, instead of CMXRos, I)iOC~, (3) was 
used as a A"t-'m-sensitive  fluorochrome  (not shown).  (B) Bcl-2-mediated 
inhibition of AIF release from isolated mitochondria.  Mitochondria from 
neo- or bcl-2-transfected cells were purified (6), diluted to a concentra- 
tion of 10 mg/ml protein in CFS buffer, and treated during 5 min at 37~ 
with Atr (5 mM), t-BHP (50 btM), or mCICCP (5(1 IxM). Alternatively, 
lnitochondria  from neo- or bcl-2-transfected  cells were  exposed to  os- 
motic shock, ultrasonication, or the detergent digitonin, followed by cen- 
trifugation. Supematants were  tested for apoptosis induction in isolated 
HeLa nuclei,  as in Fig. 1.  The inset shows cytofluorometric  profiles of 
purified mitochondria stained with an FITC-labeled hBcl-2-specific anti- 
body. (C) DNA-degrading activity ofsupernatants from control and Bcl-2 
mitochondria.  Supernatants were  generated  from  control  nfitochondria 
(I, 3) or Bcl-2-hyperexpressing mitochondria  (2, 4) exposed to Atr (1, 2) 
or osmotic shock (3, 4) as in B and were tested for induction of 1)NA 
degradation on isolated Hela cells as in Fig. 3 D. 
1336  Mechanism of Bcl-2-mediated Apoptosis Inhibition Figure  6.  Effect  of Bcl-2 on AIF action in vitro. (A) Comparison of 
AIF effects  on isolated nuclei from bcl-2-transfected and control cells cul- 
tured with different concentrations of purified AIF as in Fig. 1. The insert 
shows  cytofluorometric  profiles of nuclei  stained with  an  anti-hBcl- 
2-FITC conjugate as in Fig. 5 B. (B) Comparison of DNA degradation 
induced in nuclei from control (I, 3) or bcl-2-transfected cells (2, 4) cul- 
tured in the absence (1, 2) or presence (3, 4) of purified AIF (250 ng/ml). 
((2) Comparison of the ultrastructure of nuclei from Neo- or bcl-2-trans- 
fected cells cultured in the presence or absence of AIF (250 ng/ml;  9(1 
nfin). Typical cells representing the dominant phenotype (~>80%) of cul- 
tures are shown. 
release  a  Z-VAD.fmk-inhibitable protease  which  is  suffi- 
cient and probably necessary to cause nuclear apoptosis. 
Bcl-2  Prevents the Permeability  Transition-dependent  Release 
ofAIFfrom kqitochondria.  Bcl-2 belongs to a  family of ap- 
optosis-regulatory  proteins  which  incorporate  into  the 
outer mitochondrial membrane (31-34). Since the antiapop- 
totic mode  of action of Bcl-2 is elusive, we  addressed the 
question as to whether Bcl-2 inhibits apoptosis via interfer- 
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ing with the formation or the release ofAIF. Transfection- 
enforced  hyperexpression of Bcl-2 prevents  the  induction 
of apoptosis  by  t-BHP  and  the  mitochondrion-targeted 
agent  mC1CCP  (reference 4  and  Fig.  4).  In addition, iso- 
lated mitochondria from bcl-2 transfected cells (which hy- 
perexpress Bcl-2, see insert of Fig. 5  B)  fail to disrupt their 
Axlr,,  1 in response to Atr, the pro-oxidant t-BHP, and a low 
dose  (10  btM)  of the  protonophore  mC1CCP  (Fig.  5  A), 
thus  confirming  our  previous  observations  according  to 
which  Bcl-2  prevents  the  PT-dependent  colloidosmotic 
swelling of mitochondria in vitro (4). Simultaneously, Bcl-2 
overexpressing mitochondria fail to  release AIF activity in 
response to these PT inducers (Fig. 5, B and C), underscor- 
ing  the  absolute  correlation between  PT  and  AIF release 
that we have previously reported (4).  Thus,  AIF is present 
in  the  supernatants  of control  mitochondria  treated  with 
Atr,  t-BHP,  or mC1CCP,  yet is absent or greatly reduced 
in  the  supernatant  of Bcl-2  hyperexpressing mitochondria 
treated with these reagents. In contrast, lysis of control and 
Bcl-2-overexpressing mitochondria with  detergents  or os- 
motic shock releases equal amounts of AIF activity (Fig. 5, 
B and C). 
Thus, Bcl-2 inhibits the mitochondrial AIF release in re- 
sponse to determined stimuli but not the formation of AIF. 
Failure of Bcl-2  to Interfere with AIF Action  on  Nuclei  and 
Cells.  The  Bcl-2  p26  protein possesses a  transmembrane 
domain  allowing for its incorporation into  different intra- 
cellular  membranes,  including  the  outer  mitochondrial 
membrane,  the  endoplasmatic  reticulum,  and  the  nuclear 
envelope  (33,  34).  We  therefore  addressed  the  possibility 
that Bcl-2 might antagonize the action of AIF. In a first se- 
ries  of  experiments,  nuclei  were  purified  from  control 
(Neo) and Bcl-2 transfected cells and cultured with purified 
AIF. Bcl-2 expressing nuclei (Fig. 6 A, inse  0 undergo apop- 
totic changes in response to AIF, exactly as this is the  case 
for control nuclei (Fig. 6, A  and B).  Electron microscopic 
analysis confirmed that Bcl-2 hyperexpression does not af- 
fect  the  action  of AIF.  Both  control  and  Bcl-2-overex- 
pressing  nuclei  manifest  the  same  pattern  of  chromatin 
control  AIF  saponin  saDonin + AII 
[  Ner  A  Neo  i  Neo  [  Ner 
'~  ~  o~ '7~'  5 
Fluorscein-12-dUTP 
Figure  7.  Effect  of Bcl-2 on AIF action in cells. Failure of Bcl-2 to in- 
duce AIF resistance  in cells. Bcl-2-or vector-transfected cells were perme- 
abilized with saponin in the presence or absence of purified AIF (1  Ixg/ 
300 I*1), washed, and cultured for 60 min in CFS buffer. DNA fragmenta- 
tion was assessed  by the TUNEL method. Numbers indicate the percent- 
age of cells with strong DNA fragmentation. condensation (Fig.  6  C). Thus, nuclear expression of Bcl-2 
does not affect the action of AIF. 
Since Bcl-2 exists  also in localizations outside of the nu- 
clear  and  mitochondrial  membrane  (33),  we  decided  to 
evaluate the effect ofBcl-2 overexpression on cells exposed 
to AIF. As shown above, AIF is a hydrophilic protein and 
thus  does  not  permeate  the  plasma  membrane.  Accord- 
ingly, AIF only induces apoptotic changes in permeabilized 
cells (Fig. 7).  Introduction of AIF into saponin-treated ceils 
causes the  same  extent  of DNA fragmentation in  control 
and  in  Bcl-2-hyperexpressing cells  (Fig.  7).  Thus,  Bcl-2 
only acts  upstream, at the level of AIF release, and has no 
detectable effect on AIF action, both in cells and in isolated 
nuclei. 
Discussion 
In this paper, we provide several new elements allowing 
for the construction of a scenario recreating the apoptotic el- 
lector phase and its regulation by the proto-oncogene bcl-2. 
AIF, a Mitochondrial Apoptogenic Protease.  Mitochondria 
undergoing PT release a protein factor, AIF, which appears 
to be a pre-formed, ubiquitous  factor associated with  the 
intermembrane space (Fig.  1). AIF suffices to induce typical 
manifestations of nuclear  apoptosis in  a  cell-free, cytosol- 
free system: chromatin condensation,  chromatinolysis, hy- 
poploidy,  and  oligonucleosomal  ladder-type  DNA  frag- 
mentation  (Fig.s  1,  3,  and  6  C).  AIF  lacks  an  intrinsic 
DNAse activity, yet seems capable of activating pre-formed 
nuclear DNAses. Intriguingly enough, all in vitro activities 
of AIF are blocked by Z-VAD.fmk (Fig.  3), which is also 
an efficient inhibitor of apoptosis in mammalian and insect 
cells  (26-28  and  Fig.  4).  Although  this  is  not  a  formal 
proof,  this  finding  underlines  the  probable importance  of 
AIF  as  a  rate-limiting  factor  of the  apoptotic  process  in 
vivo. Z-VAD.fmk has been designed for the inhibition  of 
ICE-like  proteases.  However,  AIF  is  not  among  the 
known  members of the  family of ICE/CPP32/Ced3-1ike 
proteases.  Its molecular mass  (~50  kD),  subcellular local- 
ization,  and  proteolytic  spectrum  (notably the  absence  of 
PARP  cleavage) are not compatible with  those  of known 
members of the  ICE/CPP32/Ced3  family  (11).  In  addi- 
tion, preliminary NH2-terminal sequence data suggest that 
at least mouse hepatocyte AIF is encoded by a novel gene. 
Thus,  it would be premature to  consider AIF as an ICE- 
like protease,  and  the  further  characterization  of AIF will 
require its cloning and genetic manipulation. 
Is AIF the Principal Apoptogenic Factor?  Our  data  suggest- 
ing a major role of AIF in the apoptotic process are com- 
patible with previous reports that mitochondria are neces- 
sary to mediate apoptosis either in mammalian or in Xenopus 
laevis cells  (15,  16)  and that some known members of the 
ICE family such as  ICE itself or CPP32  do not suffice to 
cause apoptosis in a cell-free system (14,  17, 30, 35). More- 
over,  our data  are  compatible with  reported cell-free sys- 
tems of apoptosis with regard to the particular ion require- 
ments  of AIF  action,  which  functions  in  the  presence  of 
calcium chelators and at a neutral pH (13-17).  In contrast, 
our  results  appear to  be  in  conflict with  the  observation 
that mitochondria can be substituted for by ceramide to in- 
duce nuclear apoptosis in vitro (16). However, careful anal- 
ysis reveals a major functional difference between AIF and 
ceramide.  First,  the  apoptosis-inducing effect of ceralnide 
on cells is antagonized by Bcl-2  (2),  which  is not the case 
for AIF (Fig. 7). Second, maximal doses of C2 ceramide re- 
quire  a  minimum  of 3  h  to  induce  nuclear  apoptosis  in 
vitro (16),  whereas high doses of AIF act within  ~15  rain 
(4). Thus, AIF rather than ceramide would be a rate-limit- 
ing  apoptogenic  factor.  Nagata  and  co-workers  have  re- 
ported the existence of a cytosolic apoptogenic factor that 
is produced  upon  Pas-cross-linking (17,  35).  The method 
of isolation  to  obtain  this  factor,  repeated  freezing  and 
thawing,  would  destroy the  activity of AIF.  Interestingly, 
these  authors  have  found  that  cytosolic  extracts  treated 
with recombinant CPP32  become apoptogenic  (35).  As  a 
consequence,  it  cannot  be  excluded  that,  at  least  in  Fas- 
induced apoptosis, other factors than AIF may be involved 
in the mediation of nuclear apoptosis. Further exploration 
of these poorly characterized in vitro systems will have to 
resolve this issue.  As mentioned above, AIF fails to cleave 
nuclear PARP. Since the knock-out of the PARP gene has 
no  major effects on  apoptosis  regulation,  cleavage of this 
substrate is likely to constitute a consequence rather than a 
mechanism ofapoptosis (36).  However, since proteolysis of 
PARP is a common sign of nuclear apoptosis in cells  (37) 
and in  some cell-free systems of apoptosis  (14,  25),  addi- 
tional  (AIF-activated?) cytosolic proteases appear to be in- 
volved in the apoptotic degradation phase. 
Mode of Action of Bcl-2.  To unravel the relationship be- 
tween AIF and Bcl-2, we have investigated three mutually 
non-exclusive  possibilities.  Bcl-2  might  suppress  (a)  AIF 
synthesis; (b) AIF release; (c) or AIF action. Out data clearly 
indicate  that  Bcl-2-overexpressing  mitochondria  contain 
normal amounts of pre-formed AIF  (Fig.  5,  B and  C),  an 
observation  that  would  be  compatible  with  an  eventual 
house-keeping function of this ubiquitous protein.  Instead 
of preventing AIF formation  (Fig.  5,  B  and  C)  or action 
(Figs.  6  and 7),  Bcl-2 inhibits  the  PT-mediated release of 
AIF (Fig. 5, B and C). Our data suggest that Bcl-2 is primarily 
an inhibitor of PT (reference 4 and Fig.  5 A), in line with 
the facts  that it is mainly situated in the inner-outer mito- 
chondrial  membrane contact sites  (33,  34,  38)  (where  PT 
pores form[6]) and that its  expression level correlates stoi- 
chiometrically with one of the putative PT pore constitu- 
ents, the peripheral benzodiazepine receptor (39).  Explora- 
tion of the mechanisms how Bcl-2 regulates PT-dependent 
AIF release will require  further characterization  of the  PT 
pore complex. 
In  conclusion,  Bcl-2  suppresses  apoptotic  PT  and  AIF 
release from mitochondria, yet does not interfere with the 
formation or action of AIF. This interpretation is in accord 
with previous genetic  (40-43)  and functional data  (15,  43, 
44), suggesting that, at least in some experimental systems, 
the mitochondrial but not the nuclear localization of Bcl-2 
would  determine its  anti-apoptotic capacity. These results 
are also  compatible with the absent or marginal apoptosis- 
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Figure  8.  Hypothetical scenario ofapop- 
tosis regulation. The  scheme provides an 
overview over the temporal and mechanis- 
tic  advancement of the  apoptotic process. 
Distinct apoptosis inducing pathways acti- 
vated dunng the stimulus-dependent initia- 
tion phase of apoptosis converge at the level 
of the mitochondrion to induce pemleabil- 
ity  transition (PT), which  is  subjected to 
regulation by Bcl-2 and Bcl-2 homologues. 
PT and/or associated release of AIF triggers 
a  number  of  functionally  independent 
events: hypergeneration of reactive oxygen 
species,  a number of cytoplasnfic changes, 
nuclear apoptosis and apoptotic alterations 
of membrane  structure.  These latter are 
among the first consequences of PT, thus al- 
lowing for the heterophagic elinfination of 
apoptotic cells by adjacent cells, before full- 
blown  apoptosis occurs. At present it  re- 
mains unknown which post-PT events are 
coordinated by AIF and whether AIF di- 
rectly or indirectly engages in a self-amplify- 
ing PT-inducing feedback loop. 
inhibitory effect of Bcl-2 on cell-free systems, when Bcl-2 
protein  is  added  to  cytoplasma extracts  already  containing 
soluble pro-apoptotic factors (15,  16). 
Hierarchy between Bcl-2-  and Protease-controlled Check Points 
of the Apoptotic  Cascade.  The  present  data  may  resolve  a 
long-lasting controversy on the hierarchy between  the pu- 
tative control points of apoptosis regulated by Bcl-2/Ced-9 
and ICE/Ced-3-1ike proteases,  respectively  (9-12,  31,  32). 
According to  our data,  Bcl-2  Would prevent  apoptosis by 
maintaining  the  subcellular  compartmentalization  of AIF, 
thereby suggesting a scenario that de facto abolishes the ex- 
istence of such a hierarchy, at least at the level of the mito- 
chondrial protease.  However, it would be an oversimplifi- 
cation to assume that all proteases of the ICE/CPP32/Ced-3 
family  control  the  same  point  of the  apoptotic  cascade. 
Thus,  ICE  itself  clearly  acts  upstream  of the  PT  check 
point, in the sense that ICE activation triggered by Fas is an 
extremely rapid (< 15-30 rain)  event (35)  that precedes the 
PT-mediated  A~n,  collapse.  Inhibition  of  ICE  by  Ac- 
YVAD.cmk prevents  the  A~,,,  disruption  induced by  Fas 
cross-linking  (5).  Moreover,  recombinant  ICE  is  a  direct 
inducer  of PT in isolated mitochondria  (M.  Castedo,  S.A. 
Susin  and  G.  Kroemer,  manuscript  in  preparation).  The 
protease  inhibitors  TLCK  and  Z-VAD.fmk  can  also  pre- 
vent  the  glucocorticoid-triggered  A~,n  disruption  in  thy- 
mocytes  (8),  suggesting  the  implication  of one  or  several 
Z-VAD.fmk-inhibitable  proteases  in the  induction  of PT. 
When combined with the facts reported  in this paper,  this 
observation can be interpreted  in two  different ways. As a 
first  possibility,  one  type  of Z-VAD.fmk-inhibitable  pro- 
tease(s)  would act upstream  and another  one,  AIF, down- 
stream  of the  mitochondrion.  As a  second possibility,  AIF 
(and AIF-activated proteases)  might engage in a self-ampli- 
fication loop in which an initial triggering of PT causes AIF 
release,  which in turn  favors PT.  These  scenarios  are  cur- 
rently under active investigation. 
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A  Speculative  Model  of Apoptosis  Regulation  and  Execu- 
tion.  Current models ofapoptosis subdivide the common 
pathway into an initial  effector phase, during which the "deci- 
sion to die"  is still  subject to regulatory mechanisms,  and a 
later degradation phase,  beyond the  "point-of-no-return", 
during which the progressive augmentation of entropy due 
to  the  activation  of catabolic  enzymes  precludes  further 
regulation (3).  Collectively, our data can be embedded into 
the following working hypothesis  (Fig,  8).  Different path- 
ways  of apoptosis  induction  (some  of which  may involve 
ROS  production,  ICE  activation,  changes  in  the  expres- 
sion level  of Bcl-2/Bax  etc.)  converge  at  the  level  of the 
mitochondfion to  induce  PT  and  an  associated  Aq~  col- 
lapse. This event is controlled by Bcl-2 and probably by other 
Bcl-2 homologues located in the outer mitochondrial mem- 
brane. As a result of  PT, which marks the point-of-no-return, 
the  cell  manifests  multiple  alterations:  perturbation  of the 
plasma  membrane  structure,  increased  production  and  ac- 
tion of superoxide anion, cytoplasmic changes, and nuclear 
apoptosis  (2,  4,  8).  At least some of these  consequences of 
PT  are  dissociable  among each  other.  Thus,  the  exposure 
of phosphatidylserine  residues  on  the  outer  plasma  mem- 
brane  leaflet  precedes  hyperproduction  of superoxide  an- 
ions and does not require the presence of a nucleus (5); and 
nuclear  apoptosis  can be  observed in  P,  OS-free  conditions 
(45). Hence, it appears that these manifestations of the deg- 
radation  phase  of apoptosis  are  not  linked  among  each 
other via direct cause-effect relationships and are rather co- 
ordinated by a superior control event (8).  Future investiga- 
tions will have to determine to which extent the metabolic 
consequences  of PT such as uncoupling of the  respiratory 
chain or the PT-dependent AIF release function as coordi- 
nators of the apoptotic cascade. 
In synthesis,  the available data provide a plausible  expla- 
nation  for,  as  well  as  a  number  of testable  hypotheses  on 
the regulation of the apoptotic  effector phase by proteases, mitochondria,  and  proto-oncogenes of the  Bcl-2  family. 
The progressive unmasking of the mechanism of action of 
Bcl-2,  one  of the  major  endogenous  survival  factors  of 
lymphoid cells and one of the clinically most important on- 
coproteins, may have f:ar-reaching consequences for the ra- 
tional design of apoptosis-modulatory drugs. 
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